A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 With Temozolomide for Patients With Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2013
At a glance
- Drugs Erlotinib (Primary) ; Temozolomide
- Indications Brain cancer; Germ cell and embryonal neoplasms; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Pharmacokinetics
- 09 Feb 2006 New trial record.